Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A

Biochemical Pharmacology

Volumn 51, Issue 3, 1996, Pages 207-216

  Omar, Rabeea F ^a   Gelboin, Harry V ^b   Rahimtula, Anver D ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

inducers; inhibitors; metabolism; monoclonal antibodies; ochratoxin A; P450; toxicity

Indexed keywords

3 METHYLCHOLANTHRENE; 4 HYDROXYOCHRATOXIN A; ALKALINE PHOSPHATASE; ALPHA NAPHTHOFLAVONE; CLOFIBRATE; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; ENZYME ANTIBODY; ENZYME INDUCING AGENT; ENZYME INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; ISONIAZID; ISOSAFROLE; METYRAPONE; MONOCLONAL ANTIBODY; MYCOTOXIN; OCHRATOXIN; PHENOBARBITAL; PROTOPORPHYRIN IX COBALT; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYMURIA; LIVER MICROSOME METABOLISM; MALE; METABOLIC ACTIVATION; METABOLITE; NEPHROTOXICITY; NONHUMAN; PH; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; XENOBIOTIC METABOLISM;

EID: 0030039794     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02194-9     Document Type: Article

References (56)

1. Krogh P and Nesheim S, Ochratoxin A, Introduction. In: Environmental Carcinogens. Selected Methods of Analysis, (Eds. Stoloff L, Castegnaro M, Scott P, O'Neill IK and Bartsch H), Vol. 5, pp. 247-259. IARC Scientific Publications, No. 44, Lyon, 1982.
2. van der Merwe KJ, Steyn PS, Fourie L, Scott DB and Theron JJ, Ochratoxin A, a toxic metabolite produced by Aspergillus ochraceus WilH. Nature 205: 112-113, 1965.
3. Purchase IFH and Theron JJ, The acute toxicity of ochratoxin A to rats. Food Cosmet Toxicol 6: 479-483, 1968.
4. Peckham JC, Doupnik B Jr and Jones OH Jr, Acute toxicology of ochratoxins A and B in chicks. Appl Microbiol 21: 492-494, 1971.
5. Harwig J, Ochratoxin A and related metabolites. In: Mycotoxins (Ed. Purchase IFH), pp. 345-368. Elsevier, Amsterdam, 1974.
6. e. Krogh P, Ochratoxin. In: Mycotoxins in Human and Animal Haelth (Eds. Rodricks JV, Hesseltine CW and Mehlman MA), pp. 489-498. Pathotox Publishers, New York, 1978.
7. Berndt WO, Hayes AW and Phillips RD, Effects of mycotoxins on renal function: Mycotoxic nephropathy. Kidney Int 18: 656-664, 1980.
8. Meisner H and Meisner P, Ochratoxin A, an in vivo inhibitor of renal phosphenolpyruvate carboxykinase. Arch Biochem Biophys 208: 146-153, 1981.
9. Haubeck HD, Lorkoweski G, Kolsh E and Roschenthaler R, Immunosuppression by ochratoxin A and its prevention by phenylalanine. Appl Environ Microbiol 41: 1040-1042, 1981.
10. Kane A, Creppy EE, Roschenthaler R and Dirheimer G, Changes in urinary and renal tubular enzymes caused by sub-chronic administration of ochratoxin A to rats. Toxicology 42: 233-243, 1986.
11. Boorman G, NTP Technical Report on the Toxicology and Carcinogenesis Studies of Ochratoxin A. NTP TR358, NIH Publication No. 88-2813, Research Triangle Park, NC, 1988.
12. Bendele AM, Carlton WW, Krogh P and Lillehoj EB, Ochratoxin A carcinogenesis in the (C57BL/6JXC3H)F1 mouse. J Natl Cancer Inst 75: 733-739, 1985.
13. Creppy EE, Kane A, Dirheimer G, Lafarge-Frayssinet C, Mousset S and Frayssinet C, Genotoxicity of ochratoxin A in mice: DNA single-strand break evaluation in spleen, liver and kidney. Toxicol Lett 28: 29-35, 1985.
14. Bach PH and Bartsch H, Fungal toxins and health. Trends Pharmacol Sci 14: 424-426, 1993.
15. Stormer FC and Pederson JI, Formation of 4-OH-ochratoxin A from ochratoxin A by rat liver microsomes. Appl Environ Microbiol 39: 971-975, 1980.
16. Stormer FC, Hansen CE, Pederson JI, Hvistenhahl G and Aasen AJ, Formation of 4(R)-and 4(S)-4-hydroxyochratoxin A from ochratoxin A by liver microsomes from various species. Appl Environ Microbiol 42: 1051-1056, 1981.
17. Stormer FC, Storen O, Hansen CE, Pederson JI and Aasen AJ, Formation of 4(R)-and 4(S)-4-OH-ochratoxin A and 10-OH-ochratoxin A from ochratoxin A by rabbit liver microsomes. Appl Environ Microbiol 45: 1183-1187, 1983.
18. Ueno Y, Biotransformation of mycotoxins in the reconstituted cytochrome P-450 system. Proc Jpn Assoc Mycotoxicol 22: 28-30, 1985.
19. Oster T, Jayyosi Z, Creppy EE, El Amri HS and Batt A-M, Characterization of pig liver purified cytochrome P-450 isoenzymes for ochratoxin A metabolism studies. Toxicol Lett 57: 203-214, 1991.
20. Hietanen E, Malaveille C, Camus A-M, Bereziate J-C, Brun G, Castegnaro M, Michelon J, Idle JR and Bartsch H, Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9 mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine. Drug Metab Dispos 14: 118-126, 1986.
21. Hietanen E, Bartsch H, Bereziat J-C, Castegnaro M and Michelon J, Characterization of the cytochrome P-450 isozyme that metabolizes ochratoxin A, using metabolic inducers, inhibitors and antibodies. In: Mycotoxins, Endemic Nephropathy and Urinary Tract Tumours (Eds. Castegnaro M, Plestina R, Dirheimer G, Chernozemsky IN and Bartsch H), pp. 297-304. International Agency for Research on Cancer (IARC), Lyon, 1991.
22. Graves PE, Kaminsky LS and Halpert J, Evidence for functional and structural multiplicity of pregnenolone-16α-carbonitrile-inducible cytochrome P-450 isozymes in rat liver microsomes. Biochemistry 26: 3887-3894, 1987.
23. Guengerich FP, Wang P and Davidson N, Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits and humans using immunochemical staining coupled with SDS-polyacrylamide gel electrophoresis. Biochemistry 21: 1698-1706, 1982.
24. Fournel S, Magdalou J, Pinon P and Siest G, Differential induction of drug-metabolizing enzymes after treatment with hypolipidemic agents. Xenobiotica 17: 445-457, 1987.
25. Fischer GJ, Fukushima H and Gaylor JL, Isolation, purification, and properties of a unique form of cytochrome P-450 in microsomes of isosafrole-treated rats. J Biol Chem 256: 4388-4394, 1981.
26. Arlotto MP, Sonderfan AJ, Klaassen CD and Parkinson A, Studies on the pregnelone-16α-carbonitrile inducible form of rat liver microsomal P-450 and UDP-glucuronyl transferase. Biochem Pharmacol 36: 3859-3866, 1987.
27. Ryan DE, Ramanathan L, Iida S, Thomas PE, Haniu M, Shively JE, Lieber CS and Levin W, Characterization of a major form of rat hepatic microsomal cytochrome P450 induced by isoniazid. J Biol Chem 260: 6385-6393, 1985.
28. Drummond GS and Kappas A, The cytochrome P-450-depleted animal: An experimental model for in vivo studies in chemical biology. Proc Natl Acad Sci USA 79: 2384-2388, 1982.
29. Rahimtula AD, Zachariah PK and O'Brien PJ, Differential effects of antioxidants, steroids and other compounds on benzo(a)pyrene 3-hydroxylase activity in various tissues of rat. Br J Cancer 40: 105-112, 1979.
30. Omura T and Sato R, The carbon monoxide-binding spectrum of liver microsomes. J Biol Chem 239: 2379-2384, 1964.
31. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
32. Omar RF and Rahimtula AD, The possible role of an iron-oxygen complex in 4(S)-4-hydroxyochratoxin A formation by rat liver microsomes. Biochem Pharmacol 46: 2073-2081, 1993.
33. Jordan RA and Schenkman JB, Relationship between malondialdehyde production and arachidonic acid consumption during NADPH-supported microsomal lipid peroxidation. Biochem Pharmacol 31: 1393-1400, 1982.
34. Nakajima T, Wang R-S, Elovaara E, Park SS, Gelboin HV, Hietanen E and Vainio H, Monoclonal antibody-directed characterization of cytochrome P450 isozymes responsible for toluene metabolism in rat liver. Biochem Pharmacol 41: 395-404, 1991.
35. Werner M, Maruhn D and Atoba M, Use of gel filtration in the assay of urinary enzymes. J Chromatogr 40: 254-263, 1969.
36. Wiebel FJ, Leutz JC, Diamond L and Gelboin HV, Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in microsomes from rat tissues: Differential inhibition and stimulation by benzoflavone and organic solvents. Arch Biochem Biophys 144: 78-86, 1971.
37. Jonen HG, Hüthwohl B, Kahl R and Kahl GF, Influence of pyridine and some pyridine derivatives on spectral properties of reduced microsomes and on microsomal drug metabolizing activity. Biochem Pharmacol 23: 1319-1329, 1974.
38. Guengerich FP, Dannan GA, Wright ST, Martin MV and Kaminsky LS, Purification and characterization of liver microsomal cytochromes P-450: Electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital of β-naphthoflavone. Biochemistry 21: 6019-6030, 1982.
39. Gelboin HV, Park SS and Battula N, DNA recombinant and monoclonal antibody directed methods for determining cytochrome P-450 specificity. Biochem Pharmacol 37: 98-102, 1988.
40. Chu FS, Interaction of ochratoxin A with bovine serum albumin. Arch Biochem Biophys 147: 359-366, 1971.
41. Cho AK and Miwa GT, The role of ionization in the N-demethylation of a series of arylakylamines. Drug Metab Dispos 2: 477-483, 1973.
42. Delaforge M, Ladam P, Bouillé G, Benarous JG, Jaouen M and Girault JP, pH Effects on the N-demethylation and formation of the cytochrome P-450 iron II nitrosoalkane complex for erythromycin derivatives. Chem Biol Interact 85: 215-227, 1992.
43. Gemzik B, Halvorson MR and Parkinson A, Pronounced and differential effects of ionic strength and pH on testosterone oxidation by membrane-bound and purified forms of rat liver microsomal cytochrome P-450. J Steroid Biochem 35: 429-440, 1990.
44. scc. J Biol Chem 257: 4731-4373, 1982.
45. Khan S, Martin M, Bartsch H and Rahimtula AD, Perturbation of liver microsomal calcium homeostasis by ochratoxin A. Biochem PharmacoL 38: 67-72, 1989.
46. Miller JA, Recent studies on the metabolic activation of chemical carcinogens. Cancer Res 54 (Suppl): 1879s-1881s, 1994.
47. Gonzalez FJ and Gelboin HV, Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26: 165-183, 1994.
48. Price RG, Urinary enzymes, nephrotoxicity and renal disease. Toxicology 23: 99-134, 1982.
49. Ngaha EO and Plummer DT, Toxic renal damage: Changes in enzyme levels. Biochem Med 18: 71-79, 1977.
50. Hutchison RD, Steyn PS and Thompson DL, The isolation and structure of 4-hydroxyochratoxin A and 7-carboxy-3,4-dihydro-8-hydroxy-3-methyl isocoumarine from Penicillium veridicatum. Tetrahedron Lett 43: 4033-4036, 1971.
51. Berndt WO and Hayes AW, In vivo and in vitro changes in renal function caused by ochratoxin A in the rat. Toxicology 12: 5-17, 1979.
52. Fuchs R, Radic B, Peraica M, Huit K and Plestina R, Enterohepatic circulation of ochratoxin A in rats. Periodicum Biologorum 90: 39-42, 1988.
53. Nikolov IG, Chernozemsky IN and Idle JR, Genetic predisposition to Balkan endemic nephropathy: Ability to hydroxylate debrisoquine as a host risk factor. In: Mycotoxins, Endemic Nephropathy and Urinary Tract Tumours (Eds. Castegnaro M, Plestina R, Dirheimer G, Chernozemsky IN and Bartsch H), pp. 289-296. International Agency for Research on Cancer (IARC), Lyon, 1991.
54. Zanger UM, Vilbois F, Hardwick JP and Meyer UA, Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447-5454, 1988.
55. Baudrimont I, Betbeder A-M, Gharbi A, Pfohl-Leszkowicz A, Dirheimer G and Creppy EE, Effect of superoxide dismutase and catalase on the nephrotoxicity induced by subchronical administration of ochratoxin A to rats. Toxicology 89: 101-111, 1994.
56. Pfohl-Leszkowicz A, Gosse Y, Kane A, Gharbi A, Baudrimont I, Obrecht S, Creppy EE, and Dirheimer G, Is the oxidative pathway implicated in the genotoxicity of ochratoxin A? In: Human Ochratoxicosis and Its Pathologies (Eds. Creppy EE, Castegnaro M and Dirheimer G), Vol. 231, pp. 177-187. Colloque INSERM/ John Libbey Eurotext Ltd., Paris, 1993.